tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.58838/2075-1230-2024-102-1-82-86tiblj-1798Research ArticleОБЗОРREVIEWПрименение ингаляционных антибиотиков как одна из мер борьбы с резистентностью бактерий (на примере кистозного фиброза)Treatment with Inhaled Antibiotics as One of the Measures to Combat Bacterial Resistance (Cystic Fibrosis is Used as an Example)ТахтамышеваА. В.TakhtamyshevaA. V.

Тахтамышева Анна Валентиновна, врач-терапевт

283005, г. Донецк, ул. Диккенса, 1 

Anna V. Takhtamysheva, General Practitioner

1 Dikkens St., Donetsk, 283005

a.takhtamysheva@mail.ruГБУ «Центр первичной медико-санитарной помощи № 9 г. Донецка»ДНРDonetsk Center for Primary Medical Sanitary Care no. 9DNR20242003202410218286Copyright © Тахтамышева А.В., 20242024Тахтамышева А.В.Takhtamysheva A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1798

В представленном обзоре анализируется 33 источника литературы по эффективности ингаляционных антибиотиков у пациентов с кистозным фиброзом и определению их влияния на резистентность бактерий.

This review analyzes 33 publications on the effectiveness of inhaled antibiotics in patients with cystic fibrosis and evaluates their effect on bacterial resistance.

ингаляционные антибиотикимуковисцидозкистозный фиброзрезистентность бактерийinhaled antibioticscystic fibrosisbacterial resistanceReferencesКлинические рекомендации по ведению пациентов с кистозным фиброзом (муковисцидозом). Москва; 2021. URL: https://cr.minzdrav.gov.ru/recomend/372_2 [Дата обращения 10 декабря 2023г.]Klinicheskiye rekomendatsii po vedeniyu patsiyentov s kistoznym fibrozom (mukovistsidozom). [Guidelines on management of cystic fibrosis patients]. Moscow, 2021. Available: https://cr.minzdrav.gov.ru/recomend/372_2 Accessed December 10, 2023.Кузовлев А. Н., Мороз В. В., Голубев А. М., Половников С. Г. Ингаляционные антибиотики в лечении тяжелой нозокомиальной пневмонии / // Общая реаниматология. – 2013. – Т. 9. – № 6. – С. 61-70. https://doi.org/10.15360/1813-9779-2013-6-61Kuzovlev A.N., Moroz V.V., Golubev A.M., Polovnikov S.G. Inhaled antibiotics in the treatment of nosocomial pneumonia. Obschaya Reanimatologiya, 2013, vol. 9, no. 6, pp. 61-70. (In Russ.) https://doi.org/10.15360/1813-9779-2013-6-61Чукина М. А., Лукина М. В., Андрущишина Т. Б., и др. Ингаляционное применение амикацина у пациентов с нозокомиальной пневмонией в отделении интенсивной терапии // Вестник Смоленской государственной медицинской академии. – 2019. – Т. 18. – № 1. – С. 137-144.Chukina M.A., Lukina M.V., Andruschishina T.B. et al. Inhaled amikacin in patients with nosocomial pneumonia in the intensive care unit. Vestnik Smolenskoy Gosudarstvennoy Meditsinskoy Akademii, 2019, vol. 18, no. 1, pp. 137-144. (In Russ.)Bassetti M., Luyt C.E., Nicolau D.P., Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient // Ann Intensive Care. – 2016. – Vol.6, № 1. – Р.35. https://doi.org/10.1186/s13613-016-0140-x PMID: 27090532Bassetti M., Luyt C.E., Nicolau D.P., Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann. Intensive Care, 2016, vol. 6, no. 1, pp. 35. https://doi.org/10.1186/s13613-016-0140-x PMID: 27090532Choi J., Novak K., Thompson R. Evaluation of Inhaled Tobramycin in Early Eradication of Pseudomonas aeruginosa in Infants With Cystic Fibrosis // J Pediatr Pharmacol Ther. – 2020. – Vol 25, №8. – Р.709-716. https://doi.org/10.5863/1551-6776-25.8.709 PMID: 33214782Choi J., Novak K., Thompson R. Evaluation of inhaled tobramycin in early eradication of Pseudomonas aeruginosa in infants with cystic fibrosis. J. Pediatr. Pharmacol. Ther., 2020, vol. 25, no. 8, pp. 709-716. https://doi.org/10.5863/1551-6776-25.8.709 PMID: 33214782ClinicalTrials.gov: NCT01270347 Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS) Available at: https://ichgcp.net/clinical-trials-registry/NCT01270347 [Accessed 15 Dec 2022].ClinicalTrials.gov: NCT01270347 Trial of aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients (TIS). Available: ehttps://ichgcp.net/clinical-trials-registry/NCT01270347 Accessed December 15, 2022Daniels T., Mills N., Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis // Cochrane Database Syst Rev. – 2013. – Vol.30, № 4. – Р.CD007639. https://doi.org/10.1002/14651858 PMID:23633344Daniels T., Mills N., Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst. Rev., 2013, vol. 30, no. 4, pp. CD007639. https://doi.org/10.1002/14651858 PMID:23633344Dasenbrook E.C., Konstan M.W., VanDevanter D.R. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes // J Cyst Fibros. – 2015. – Vol.14, №3. – Р.370-5. https://doi.org/10.1016/j.jcf.2014.11.005 PMID: 25496726Dasenbrook E.C., Konstan M.W., VanDevanter D.R. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J. Cyst. Fibros., 2015, vol. 14, no. 3, pp. 370-5. https://doi.org/10.1016/j.jcf.2014.11.005 PMID: 25496726Dezube R., Jennings M.T., Rykiel M., Diener-West M., Boyle M.P., Chmiel J.F., Dasenbrook E.C. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis // J Cyst Fibros. – 2019. – Vol.18, №3. – Р.357-363. https://doi.org/10.1016/j.jcf.2018.07.005 PMID: 30131297Dezube R., Jennings M.T., Rykiel M., Diener-West M., Boyle M.P., Chmiel J.F., Dasenbrook E.C. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J. Cyst. Fibros., 2019, vol. 18, no. 3, pp. 357-363. https://doi.org/10.1016/j.jcf.2018.07.005 PMID: 30131297Ekkelenkamp M.B., Díez-Aguilar M., Tunney M.M., Elborn J.S., Fluit A.C., Cantón R. Establishing Antimicrobial Susceptibility Testing Methods and Clinical Breakpoints for Inhaled Antibiotic Therapy // Open Forum Infect Dis. // 2022. – Vol.9,№4. – Р.ofac082. https://doi.org/10.1093/ofid/ofac082 PMID: 35265731Ekkelenkamp M.B., Díez-Aguilar M., Tunney M.M., Elborn J.S., Fluit A.C., Cantón R. Establishing antimicrobial susceptibility testing methods and clinical breakpoints for inhaled antibiotic therapy. Open Forum Infect. Dis., 2022, vol. 9, no. 4, pp. ofac082. https://doi.org/10.1093/ofid/ofac082 PMID: 35265731Elborn J.S., Flume P.A., Cohen F., Loutit J., VanDevanter D.R. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection // J Cyst Fibros. – 2016. – Vol.15, №5. – Р.634-40. https://doi.org/10.1016/j.jcf.2016.01.005 PMID: 26935334Elborn J.S., Flume P.A., Cohen F., Loutit J., VanDevanter D.R. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J. Cyst. Fibros., 2016, vol. 15, no. 5, pp. 634-40. https://doi.org/10.1016/j.jcf.2016.01.005 PMID: 26935334Goetz D., Ren C.L. Review of Cystic Fibrosis // Pediatr Ann. – 2019. – Vol.48,№4. –Р.e154-e161. https://doi.org/10.3928/19382359-20190327-01 PMID: 30986316Goetz D., Ren C.L. Review of cystic fibrosis. Pediatr. Ann., 2019, vol. 48, no. 4, pp. e154-e161. https://doi.org/10.3928/19382359-20190327-01 PMID: 30986316Hatziagorou E., Orenti A., Drevinek P., Kashirskaya N., Mei-Zahav M., De Boeck K; ECFSPR. Electronic address: ECFS-Patient.Registry@uz.kuleuven. ac.be; ECFSPR. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry // J Cyst Fibros. –2020. – Vol.19, № 3. – Р.376-383. https://doi.org/10.1016/j.jcf.2019.08.006 PMID: 31492646Hatziagorou E., Orenti A., Drevinek P., Kashirskaya N., Mei-Zahav M., De Boeck K; ECFSPR. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry. J. Cyst. Fibros., 2020, vol. 19, no. 3, pp. 376-383. https://doi.org/10.1016/j.jcf.2019.08.006 PMID: 31492646Henriette Zweijpfenning S.M., Chiron R., Essink S., Schildkraut J., Akkerman O.W., Aliberti S., Altenburg J., Arets B., van Braeckel E., Delaere B., Gohy S., Haarman E., Lorent N., McKew G., Morgan L., Wagner D., van Ingen J., Hoefsloot W. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study // Chest. – 2022. – Vol.162, №1. –Р.76-81. https://doi.org/10.1016/j.chest.2022.01.015 PMID: 35063454Henriette Zweijpfenning S.M., Chiron R., Essink S., Schildkraut J., Akkerman O.W., Aliberti S., Altenburg J., Arets B., van Braeckel E., Delaere B., Gohy S., Haarman E., Lorent N., McKew G., Morgan L., Wagner D., van Ingen J., Hoefsloot W. Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: A NTM-NET study. Chest, 2022, vol. 162, no. 1, pp. 76-81. https://doi.org/10.1016/j.chest.2022.01.015 PMID: 35063454Hoo Z.H., Curley R., Campbell M.J., Walters S.J., Hind D., Wildman MJ. Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence" // Patient Prefer Adherence. – 2016. – Vol. 23, №10. –Р.887-900. https://doi.org/10.2147/PPA.S105530 PMID: 27284242Hoo Z.H., Curley R., Campbell M.J., Walters S.J., Hind D., Wildman MJ. Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence". Patient Prefer Adherence, 2016, vol. 23, no. 10, pp. 887-900. https://doi.org/10.2147/PPA.S105530 PMID: 27284242Jennings M.T., Boyle M.P., Weaver D., Callahan K.A., Dasenbrook E.C. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis--the PMEP trial: study protocol for a randomized controlled trial // Trials. –2014. –№ 15. – Р.223. https://doi.org/10.1186/1745-6215-15-223 PMID: 24925006Jennings M.T., Boyle M.P., Weaver D., Callahan K.A., Dasenbrook E.C. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis – the PMEP trial: study protocol for a randomized controlled trial. Trials, 2014, no. 15, pp. 223. https://doi.org/10.1186/1745-6215-15-223 PMID: 24925006Jones L.A., Doucette L., Dellon E.P., Esther C.R., McKinzie C.J. Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series // J Cyst Fibros. – 2019. – Vol.18, №4. – e42-e44. https://doi.org/10.1016/j.jcf.2019.04.017 PMID: 31060800Jones L.A., Doucette L., Dellon E.P., Esther C.R., McKinzie C.J. Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series. J. Cyst. Fibros., 2019, vol. 18, no. 4, pp. e42-e44. https://doi.org/10.1016/j.jcf.2019.04.017 PMID: 31060800Karampitsakos T., Papaioannou O., Kaponi M., Kozanidou A., Hillas G., Stavropoulou E., Bouros D., Dimakou K. Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis // Pulm Pharmacol Ther. – 2020. – №60. – Р.101885. https://doi.org/10.1016/j.pupt.2019.101885 PMID: 31891761.Karampitsakos T., Papaioannou O., Kaponi M., Kozanidou A., Hillas G., Stavropoulou E., Bouros D., Dimakou K. Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis. Pulm. Pharmacol. Ther., 2020, no. 60, pp. 101885. https://doi.org/10.1016/j.pupt.2019.101885 PMID: 31891761Kiefer A., Bogdan C., Melichar V.O. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme // BMC Pulm Med. – 2018. – Vol.18, №1. –Р.20. https://doi.org/10.1186/s12890-018-0588-6 PMID: 29370836Kiefer A., Bogdan C., Melichar V.O. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm. Med., 2018, vol. 18, no. 1, pp. 20. https://doi.org/10.1186/s12890-018-0588-6 PMID: 29370836Kuzovlev, A. N. Inhaled Antibiotics in Reanimatology: Problem State and Development Prospects (Review) / A. N. Kuzovlev, A. V. Grechko // General Reanimatology. – 2017. – Vol. 13. – № 5. – P. 69-84. https://doi.org/10.15360/1813-9779-2017-5-69-84Kuzovlev A.N. Inhaled Antibiotics in Reanimatology: Problem State and Development Prospects (Review). A.N. Kuzovlev, A.V. Grechko. General Reanimatology, 2017, vol. 13, no. 5, pp. 69-84. https://doi.org/10.15360/1813-9779-2017-5-69-84Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis // Cochrane Database Syst Rev. – 2017. – Vol. 4, №4. – Р.CD004197. https://doi.org/10.1002/14651858.CD004197.pub5 PMID: 28440853Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev., 2017, vol. 4, no. 4, pp. CD004197. https://doi.org/10.1002/14651858.CD004197.pub5 PMID: 28440853Lebeaux D., Chauhan A., Rendueles O., Beloin C. From in vitro to in vivo Models of Bacterial Biofilm-Related Infections // Pathogens. –2013. – Vol 2, № 2. – Р.288-356. https://doi.org/10.3390/pathogens2020288 PMID: 25437038Lebeaux D., Chauhan A., Rendueles O., Beloin C. From in vitro to in vivo Models of Bacterial Biofilm-Related Infections. Pathogens, 2013, vol. 2, no. 2, pp. 288-356. https://doi.org/10.3390/pathogens2020288 PMID: 25437038Lebeaux D., Ghigo J.M., Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics // Microbiol Mol Biol Rev. – 2014. – Vol.78, 3. –Р. 510-43. https://doi.org/10.1128/MMBR.00013-14 PMID: 25184564Lebeaux D., Ghigo J.M., Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev., 2014, vol. 78, 3. pp. 510-43. https://doi.org/10.1128/MMBR.00013-14 PMID: 25184564Møller R., Nielsen B.U., Faurholt-Jepsen D., Katzenstein T.L., Skov M., Philipsen L.KD, Pressler T., Johansen H.K, Qvist T. Use of inhaled antibiotics among Danish patients with cystic fibrosis // Pediatr Pulmonol. – 2022. – Vol.57, №7. – Р.1726-1734. https://doi.org/10.1002/ppul.25942 PMID: 35478387Møller R., Nielsen B.U., Faurholt-Jepsen D., Katzenstein T.L., Skov M., Philipsen L.KD, Pressler T., Johansen H.K, Qvist T. Use of inhaled antibiotics among Danish patients with cystic fibrosis. Pediatr. Pulmonol., 2022, vol. 57, no. 7, pp. 1726-1734. https://doi.org/10.1002/ppul.25942 PMID: 35478387Quon B.S., Goss C.H., Ramsey B.W. Inhaled antibiotics for lower airway infections // Ann Am Thorac Soc. – 2014. – Vol.11, № 3. – Р.425-34. https://doi.org/10.1513/AnnalsATS.201311-395FR PMID: 24673698Quon B.S., Goss C.H., Ramsey B.W. Inhaled antibiotics for lower airway infections. Ann. Am. Thorac. Soc., 2014, vol. 11, no. 3, pp. 425-34. https://doi.org/10.1513/AnnalsATS.201311-395FR PMID: 24673698Riveiro V., Casal A., Álvarez-Dobaño J.M., Lourido T., Suárez-Artime P., Rodríguez-García C., Ferreiro L., Toubes M.E., Valdés L. Response to inhaled ceftazidime in patients with non-cystic fibrosis bronchiectasis and chronic bronchial infection unrelated to Pseudomonas aeruginosa.– Clin Respir J. – 2022. – Vol. 16, №11.Riveiro V., Casal A., Álvarez-Dobaño J.M., Lourido T., Suárez-Artime P., Rodríguez-García C., Ferreiro L., Toubes M.E., Valdés L. Response to inhaled ceftazidime in patients with non-cystic fibrosis bronchiectasis and chronic bronchial infection unrelated to Pseudomonas aeruginosa. Clin. Respir. J., 2022, vol. 16, no. 11, pp. 768-773. https://doi.org/10.1111/crj.13534 PMID: 36017771Stockmann C., Sherwin C.M., Ampofo K., Spigarelli M.G. Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis // Ther Adv Respir Dis. – 2014. – Vol.8, № 1. – Р. 13-21. https://doi.org/10.1177/1753465813508445 PMID: 24334337Stockmann C., Sherwin C.M., Ampofo K., Spigarelli M.G. Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Ther. Adv. Respir. Dis., 2014, vol. 8, no. 1, pp. 13-21. https://doi.org/10.1177/1753465813508445 PMID: 24334337Tiddens H.A., Bos A.C., Mouton J.W., Devadason S., Janssens H.M. Inhaled antibiotics: dry or wet? // Eur Respir J. – 2014. – Vol.44, № 5. – Р.1308-18. https://doi.org/10.1183/09031936.00090314 PMID: 25323242.Tiddens H.A., Bos A.C., Mouton J.W., Devadason S., Janssens H.M. Inhaled antibiotics: dry or wet? Eur. Respir. J., 2014, vol. 44, no. 5, pp. 1308-18. https://doi.org/10.1183/09031936.00090314 PMID: 25323242Vázquez-Espinosa E., Girón R.M., Gómez-Punter R.M., García-Castillo E., Valenzuela C., Cisneros C., Zamora E., García-Pérez F..J, Ancochea J. Long-term safety and efficacy of tobramycin in the management of cystic fibrosis // Ther Clin Risk Manag. – 2015. –№ 11. – Р.407-15. https://doi.org/10.2147/TCRM.S75208 PMID: 25792839Vázquez-Espinosa E., Girón R.M., Gómez-Punter R.M., García-Castillo E., Valenzuela C., Cisneros C., Zamora E., García-Pérez F.J., Ancochea J. Long-term safety and efficacy of tobramycin in the management of cystic fibrosis. Ther. Clin. Risk Manag., 2015, no. 11, pp. 407-15. https://doi.org/10.2147/TCRM.S75208 PMID: 25792839Wang M., Ridderberg W., Hansen C.R., Høiby N., Jensen-Fangel S., Olesen H.V., Skov M., Lemming L.E., Pressler T., Johansen H.K., Nørskov-Lauritsen N. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis // J Cyst Fibros. – 2013. – Vol.12, № 6. – Р. 638-43. https://doi.org/10.1016/j.jcf.2013.04.013 PMID: 23727271Wang M., Ridderberg W., Hansen C.R., Høiby N., Jensen-Fangel S., Olesen H.V., Skov M., Lemming L.E., Pressler T., Johansen H.K., Nørskov-Lauritsen N. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J. Cyst. Fibros., 2013, vol. 12, no. 6, pp. 638-43. https://doi.org/10.1016/j.jcf.2013.04.013 PMID: 23727271Weldrick P.J., Hardman M.J., Paunov V.N. Enhanced Clearing of Wound-Related Pathogenic Bacterial Biofilms Using Protease-Functionalized Antibiotic Nanocarriers // ACS Appl Mater Interfaces. – 2019. – Vol.11, 47. – Р.43902-43919. https://doi.org/10.1021/acsami.9b16119 PMID: 31718141Weldrick P.J., Hardman M.J., Paunov V.N. Enhanced Clearing of Wound-Related Pathogenic Bacterial Biofilms Using Protease-Functionalized Antibiotic Nanocarriers. ACS Appl. Mater. Interfaces, 2019, vol. 11, 47. pp. 43902-43919. https://doi.org/10.1021/acsami.9b16119 PMID: 31718141White L., Mirrani G., Grover M., Rollason J., Malin A., Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis // Respir Med. – 2012. – Vol. 106, № 3. – Р.356-60. https://doi.org/10.1016/j.rmed.2011.11.018 PMID: 22204744.White L., Mirrani G., Grover M., Rollason J., Malin A., Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir. Med., 2012, vol. 106, no. 3, pp. 356-60. https://doi.org/10.1016/j.rmed.2011.11.018 PMID: 22204744Zobell J.T., Epps K.L., Young D.C., Montague M., Olson J., Ampofo K., Chin M.J., Marshall B.C., Dasenbrook E. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis // Pediatr Pulmonol. – 2015. – Vol. 50, №6. – Р. 552-9. https://doi.org/10.1002/ppul.23132 PMID: 25559432Zobell J.T., Epps K.L., Young D.C., Montague M., Olson J., Ampofo K., Chin M.J., Marshall B.C., Dasenbrook E. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr. Pulmonol., 2015, vol. 50, vol. 6, pp. 552-9. https://doi.org/10.1002/ppul.23132 PMID: 25559432

The authors declare that there are no conflicts of interest present.